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Abstract
CD36 is the major receptor mediating nonopsonic phagocytosis of Plasmodium falciparum-parasitized erythrocytes by
macrophages. Its expression on macrophages is mainly controlled by the nuclear receptor PPARc. Here, we demonstrate
that inflammatory processes negatively regulate CD36 expression on human and murine macrophages, and hence decrease
Plasmodium clearance directly favoring the worsening of malaria infection. This CD36 downregulation in inflammatory
conditions is associated with a failure in the expression and activation of PPARc. Interestingly, using siRNA mediating knock
down of Nrf2 in macrophages or Nrf2- and PPARc-deficient macrophages, we establish that in inflammatory conditions, the
Nrf2 transcription factor controls CD36 expression independently of PPARc. In these conditions, Nrf2 activators, but not
PPARc ligands, enhance CD36 expression and CD36-mediated Plasmodium phagocytosis. These results were confirmed in
human macrophages and in vivo where only Nrf2 activators improve the outcome of severe malaria. Collectively, this report
highlights that the Nrf2 transcription factor could be an alternative target to PPARc in the control of severe malaria through
parasite clearance.
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Introduction
Mononuclear phagocytes represent the first line of innate
immune defense against pathogens through mechanisms involving
recognition by pattern-recognition receptors (PRRs) of highly
structurally conserved microbial structures, known as pathogen-
associated molecularpatterns [1]. AmongthePRRsfamily, the class
B scavenger receptor CD36, initially known as a receptor for the
uptake of oxidatively low density lipoprotein, also mediates the
recognition and the elimination of apoptotic cells and bacteria [2,3].
Additionally, the CD36 receptor specifically recognizes Plasmodium
falciparum parasitized-erythrocytes (PfPEs), resulting in a CD36-
dependent nonopsonic phagocytosis of PfPEs and a decrease in
parasite-inducedTNF-a secretion[4].Consistently,CD36-deficient
macrophages displayed a marked phagocytic defect for parasitized
erythrocytes compared with wild-type macrophages [5]. Further-
more, a recent study demonstrates in vivo the importance of CD36
receptor expression on macrophages during malaria infection.
Indeed, CD36
2/2 mice present a defect in parasite clearance [5].
CD36 expression is under the transcriptional control of a
PPARc nuclear receptor. As a consequence, PPARc ligands, such
as thiazolidinediones, or IL4 and IL13 Th2 cytokines, promote
CD36 expression on macrophages [6–8]. Moreover, rosiglitazone
and IL13 have been shown to promote in vitro an increase in
CD36-mediated phagocytosis and a decrease in malaria parasite-
induced TNF-a release both on murine macrophage and human
monocytes [4,8,9]. More recently, rosiglitazone treatment has
been shown in vivo to reduce parasitemia level in the Plasmodium
chabaudi chabaudi AS murine experimental model through the
CD36 pathway [9]. Pharmacological modulation of CD36
expression on macrophages might therefore contribute to enhance
parasite elimination and limit host inflammatory deleterious
response to malaria infection.
Nevertheless, much of the pathology associated with malaria
infection is a result of excessive and uncontrolled production of
proinflammatory markers and cytokines [10,11]. In this acute
malaria inflammatory context, we previously demonstrated that
CD36 receptor expression was reduced on the surface of
circulating monocytes from P. falciparum infected patients [12].
In line with this, Th1 cytokines, such as TNF-a and IFNc decrease
CD36 expression both on monocytes and macrophages [13,14].
Interestingly, this CD36 downregulation was correlated with a
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[13]. Collectively, all these data suggest that inflammatory
processes might negatively regulate PPARc expression and
activation in macrophages.
Surprisingly, PPARc
2/2 macrophages did not present a totally
abolished CD36 phenotype [8,15]. This data suggests the
existence of alternative pathways controlling CD36 expression
on macrophages. In this study, we focused on NF-E2 related factor
2 (Nrf2), a transcription factor involved in the prevention of severe
inflammatory diseases [16], that is activated in response to
oxidative stress and electrophiles agents, such as sulforaphane or
diethylmaleate. We previously demonstrated that the anti-TNFa
antibody treatment increased CD36 expression on human
monocytes through the enhancement of reactive oxygen species
production independently of PPARc [13]. Nrf2 was also shown to
play an important role in the regulation of CD36 expression [17–
19]. We therefore postulated that Nrf2 transcription factor might
substitute PPARc to promote CD36 expression and hence CD36-
mediated phagocytosis of PfPEs during acute inflammatory
processes.
In this study, we show in vitro on murine and human
monocytes-derived macrophages (hMDMs) and in vivo in murine
inflammatory-induced severe malaria model, that inflammatory
processes downregulate CD36 expression and CD36-mediated
Plasmodium clearance, exacerbating the development of severe
malaria infection. In acute inflammatory conditions, PPARc
ligands were unable to promote CD36 expression and subse-
quently to restore the loss of CD36-mediated Plasmodium
clearance. Interestingly, we demonstrate the existence of an
alternative pathway controlling CD36 expression in inflammato-
ry conditions independently of PPARc both on murine and
human inflammatory macrophages. We established in vitro and in
vivo that the Nrf2 transcription factor is essential to promote
CD36 expression and Plasmodium clearance and therefore control
malaria infection. This report highlights that Nrf2 transcription
factor could be a therapeutic target in the control of severe
malaria infection.
Results
Inflammatory conditions decrease CD36 expression and
CD36 mediated-Plasmodium PEs phagocytosis through
the downregulation of PPARc
To determine the effect of inflammation on the modulation of
CD36 expression, murine peritoneal macrophages were treated
during 24 h for the quantification of CD36 protein level and
during 5 h for mRNA level with TNF-a, peptidoglycan (PGN), or
were incubated in presence of P. falciparum culture supernatant (P.f.
cs) to mimic a more physiological malaria inflammatory context.
The analysis of CD36 protein level on cells was evaluated on a
selected R1 region, in which 92,2% of the cells were F4/80 and
CD36 double-positive (Fig. S1A). Fig. 1A shows that TNF-a, PGN
and P.f. cs treatments significantly decreased CD36 protein level.
Consistent with this data, CD36 mRNA level was also downreg-
ulated following TNF-a, PGN and P.f. cs treatments (Fig. 1B). To
assess whether TLR signaling directly leads to reduced CD36
expression or if the effects mediated by PGN or P.f. cs are
dependent on TNF-a production, we evaluated CD36 protein
level in presence of an anti-TLR2 antibody or etanercept, a potent
TNF-a inhibitor. We demonstrated that PGN and P.f.c s
treatments downregulate CD36 expression through TLR2
(Fig. 1C). The use of etanercept, unequivocally prove that the
effects mediated by TLR2 activators on macrophage CD36
expression are independent of TNF-a production (Fig. 1C).
We then evaluated whether rosiglitazone and IL13, known to
promote CD36 expression via an activation of the nuclear receptor
PPARc, could reverse the downregulation of CD36 receptor induced
by inflammatory conditions. Murine peritoneal macrophages were
firstly treated for 24 h with TNF-a, peptidoglycan (PGN) or P.f. cs
and were then incubated for an additional time with rosiglitazone or
IL13. Fig. 1A and FACS profiles (Fig. S1B, S1C) showed that
rosiglitazone and IL13 increased CD36 protein level in noninflam-
matory conditions (control). However, in an inflammatory context
both rosiglitazone and IL13 treatments failed to increase the CD36
protein and mRNA levels (Fig. 1A, 1B, S1B, S1C). These data
demonstrate that inflammation negatively regulates CD36 expression
and reveals the failure of PPARc ligands to promote CD36
expression on macrophages in these conditions.
To determine whether these inflammatory conditions were also
associated with an impaired P. falciparum clearance, the ability of
macrophages to phagocytose PfPEs was assessed. Fig. 1D showed a
significantly reduced ability of macrophages to eliminate PfPEs in
inflammatory conditions (TNF-a, PGN, P.f. cs). In addition, IL13
was not able to restore the decrease of CD36-mediated
phagocytosis of PfPEs observed in inflammatory conditions
(Fig. 1D). Therefore, the failure of PPARc activators to promote
CD36 expression and its PfPEs phagocytosis-associated function in
inflammatory conditions strongly suggests that PPARc is no longer
able to exert its transcriptional activity on the CD36 promoter.
To investigate whether the failure in CD36-dependent PPARc
transcriptional activity was correlated with a lower level of PPARc
expression, we evaluated PPARc protein and mRNA levels in an
inflammatory context. Interestingly, TNF-a, PGN and P.f. cs
significantly decreased PPARc protein and mRNA expressions
(Fig. 1E). All these observations indicate that the inability of
PPARc ligands to enhance CD36 expression and its antimalarial
associated functions in inflammatory conditions was associated
with a marked decrease of PPARc expression.
Author Summary
Severe and fatal malaria is still increasing both in incidence
and in its resistance to antimalarial agents. The improved
understanding of immune mechanisms mediating Plasmo-
dium elimination might therefore offer a complementary
way to conventional therapeutic interventions. The main
host innate immune defense mechanism against Plasmo-
dium falciparum is the engulfment by macrophages
through CD36, the macrophage receptor recognizing
infected erythrocytes. The up-regulation of CD36 on
macrophages therefore represents an alternative way to
favor parasite clearance during infection. Severe malaria
infection is associated with an excessive production of
proinflammatory markers and an inability to control
parasite proliferation. We demonstrate here that malaria-
induced inflammation down regulates CD36 expression on
macrophages and favors the worsening of malaria
infection. The conventional way to promote CD36
expression through PPARc nuclear receptor is inefficient
under malaria inflammatory processes. Interestingly, we
establish that the Nrf2 transcription factor may substitute
PPARc to promote CD36 expression and its associated
functions in inflammatory conditions. As a consequence,
only Nrf2 but not PPARc activators improve the outcome
of severe malaria in vivo. This paper which highlights a
new area of application for Nrf2 activators in infectious
diseases, heralds the emergence of a new therapeutic
strategy against severe malaria.
Nrf2 Promotes CD36 Antimalarial Activity
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CD36-mediated Plasmodium falciparum-PEs
phagocytosis in inflammatory conditions
We hypothesized that the Nrf2 transcription factor, recently
known to control the CD36 expression, could substitute the
deficiency of PPARc in acute inflammatory conditions to enhance
the expression of the CD36 receptor. Murine macrophages were
firstly treated over 24 h with TNF-a, PGN or P.f. cs and then
incubated for an additional time with Nrf2 activators sulforaphane
(SFN) or diethylmaleate (DEM). Fig. 2A and FACS profiles (Fig.
S2A, S2B) demonstrate that sulforaphane (SFN) and diethylmale-
ate (DEM) increase the CD36 protein level both in noninflam-
matory (control) and in an inflammatory context (TNF-a, PGN or
Pfcs). Consistent with this data, the same profiles of CD36 mRNA
were obtained (Fig. 2B). Then, the study of CD36 protein level
after the administration of Nrf2 or PPARc activators before the
onset of inflammation demonstrate that both Nrf2 and PPARc
ligands prevent the downregulation of CD36 expression. (Fig.
S2C).
In parallel, we showed that Nrf2 activators also up-regulate
PPARc mRNA levels in an Nrf2-dependent manner (Fig. S2E,
S2F). However, no synergistic effect between PPARc and Nrf2
activators has been observed in vitro on macrophage CD36
expression in inflammatory conditions (Fig. S2D).
We then explored whether this CD36 up-regulation by Nrf2
activators during inflammatory conditions could restore the
decrease of CD36-mediated phagocytosis of PfPEs observed
during inflammation. Fig. 2C reveals that an SFN treatment both
in noninflammatory (control) and inflammatory conditions (TNF-
a) enhanced the phagocytosis of PfPEs. These inductions were
abolished by the use of a CD36 specific antibody (a-CD36),
demonstrating that these phagocytic processes were dependent of
the CD36 receptor.
To validate that the transcriptional activity of Nrf2 was still
effective under inflammatory conditions, we next studied the
modulation of HO-1 gene expression, a specific Nrf2 target gene
[18]. Both in noninflammatory (control) and inflammatory (TNF-
a) conditions, SFN and DEM significantly increased HO-1 mRNA
expression, while PPARc activators (IL13 or rosiglitazone) did not
change HO-1 mRNA level (Fig. 2D), demonstrating that Nrf2
transcriptional activity was still efficient in inflammatory condi-
tions. Altogether, these results suggest that the Nrf2 transcriptional
factor could be involved in the regulation of CD36 expression and
hence in CD36-mediated PfPEs phagocytosis in inflammatory
conditions.
Nrf2 activators promote CD36 expression independently
of PPARc
To establish that the Nrf2 transcription factor may promote
CD36 expression in absence of the PPARc nuclear receptor, we
performed experimentson the RAW 264.7macrophage murine cell
line which expresses a very low level of PPARc, as demonstrated in
Fig. 3A. Fig. 3B shows that PPARc specific activators, IL13 and
rosiglitazone, did not change the CD36 protein level, whereas the
Nrf2 activators (SFN or DEM) strongly enhanced CD36 protein
expression (Fig. 3B). These results show that in absence of PPARc,
Nrf2 activators are able to promote CD36 expression.
To further confirm that PPARc was not involved in the
regulation of CD36 by Nrf2 activators, murine macrophages were
incubated in the presence of GW9662 or T007, two specific
irreversible antagonists of PPARc. Fig. 3C shows that the
macrophages treated by GW9662 or T007 failed to up-regulate
CD36 expression after exposure to IL13. In contrast, GW9662 or
T007 treatmentsdidnot affectCD36 over-expression observedwith
SFN or DEM treatments. Altogether these data prove that the
induction of CD36 by Nrf2 activators is independent of PPARc.
Finally, to unequivocally prove that Nrf2 activators could
promote CD36 expression in absence of PPARc, we studied CD36
mRNA expression in macrophages in which PPARc had been
selectively disrupted. As expected, the expression of CD36 was
promoted by rosiglitazone, IL13, SFN or DEM treatments in
macrophages from PPARc
+/+ mice. Interestingly, the CD36 over-
expression following rosiglitazone or IL13 treatments failed in
PPARc deficient macrophages (PPARc
2/2), while SFN or DEM
treatments enhanced CD36 expression in PPARc
2/2 cells
(Fig. 3D). In line, the PfPEs phagocytosis level by PPARc
2/2
macrophages was only enhanced following SFN or DEM
treatments and not by rosiglitazone or IL13 (Fig. 3E). Altogether
these data establish that only Nrf2 activators contribute to the
enhancement of CD36 expression and CD36 mediated-P.
falciparum phagocytosis in absence of PPARc.
Nrf2 activation is involved in CD36 induction during
inflammatory conditions
To confirm the specific involvement of Nrf2 transcription factor
in the regulation of CD36 expression under inflammatory
conditions, TNF-a activated macrophages were transiently
transfected with siRNA specifically targeting Nrf2. As predicted,
the siRNA-mediated knock down of Nrf2 decreased HO-1
expression in TNF-a treated macrophages following SFN or
DEM treatments (Fig. S3A, S3B). Interestingly, the increase of
CD36 mRNA level both in TNF-a treated macrophages (Fig. 4A)
and RAW cells (Fig. 4B) following SFN or DEM treatments was
abolished after transfection with siRNA targeting Nrf2. These data
strongly suggest that the up-regulation of CD36 in inflammatory
context is mediated by Nrf2 transcription factor.
To consolidate our hypothesis, we studied CD36 and HO-1
mRNA levels in macrophages from Nrf2
2/2 mice. The induction
of CD36 (Fig. 4C) and HO-1 (Fig. S3C) mRNA levels by SFN or
DEM treatments in macrophages from Nrf2
+/+ mice both in
normal (control) and in inflammatory conditions (TNF-a) was not
observed in macrophages from Nrf2
2/2 mice. Consistently, the
Figure 1. Inflammatory conditions decrease CD36 expression and CD36-mediated PfPEs phagocytosis through downregulation of
PPARc. (A–B) CD36 protein and mRNA levels detected by flow cytometry or qRT-PCR on Swiss murine peritoneal macrophages firstly treated during
24 h with TNF-a (10 ng/mL), peptidoglycan (PGN) (1 mg/mL) or Plasmodium falciparum culture supernatant (P.f. c s) and incubated during 20
supplementary hours with rosiglitazone (R) (5 mM) or IL13 (50 ng/mL) for protein quantification or 5 supplementary hours for mRNA detection. Data
are represented as a mean 6 SD of three independent experiments. **p,0.01 compared with control cells (untreated). (C) CD36 protein level
detected by flow cytometry on macrophages pre-incubated with a TL2 blocking monoclonal antibody (Anti-TLR2 mAb) (10 mg/mL) or Etanercept, a
TNF-a inhibitor (10 mg/mL), and stimulated with TNF-a (10 ng/mL), PGN (1 mg/mL) or P.f. cs. Data are from a representative experiment performed in
triplicate 6 SD. **p,0.01 compared with control cells (untreated).
##p,0.01 compared with the respective control (Etanercept treated cells). (D)
Phagocytosis index of P. falciparum unopsonized erythrocytes by Swiss murine macrophages stimulated as described in (A). Data are from a
representative experiment performed in triplicate 6 SD. The experiment was repeated three times. *p,0.05 and **p,0.01 compared with control
cells (untreated). (E) PPARc protein and mRNA levels in Swiss macrophages were determined by qRT-PCR after treatment of cells with TNF-a, PGN or
P.f. cs. Data are represented as a mean 6 SD of three independent experiments for mRNA quantification. **p,0.01 compared with control cells (C).
doi:10.1371/journal.ppat.1002254.g001
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DEM treatments in Nrf2
2/2 macrophages (Fig 4D). Altogether,
these data clearly revealed that Nrf2 plays a crucial role in the
activation of CD36 macrophage gene expression and in its
phagocytosis-associated functions during acute inflammatory
processes.
To evaluate the DNA-binding activity of Nrf2 transcription
factor in inflammatory conditions, a DNA-binding ELISA-based
assay using a specific Nrf2 antibody was performed. Fig. 5A
demonstrates that Nrf2 was specifically activated by SFN
treatment and bound to its ARE-binding sequence both in
noninflammatory and in inflammatory (TNF-a) conditions. Fig. 5B
reveals that the Nrf2 protein level was increased in the nucleus of
SFN-treated cells both in noninflammatory and in inflammatory
(TNF-a) conditions. Then, to evaluate this nuclear localization of
Nrf2 following SFN treatment, confocal laser scanning microscopy
analysis was performed. Nrf2 transcription factor was localized
both in the nucleus and in the cytoplasm of control and TNF-a
Figure 2. Nrf2 activators promote CD36 expression and enhance CD36-mediated PfPEs phagocytosis in inflammatory conditions.
(A–B) CD36 protein and mRNA levels detected by flow cytometry or qRT-PCR on Swiss murine peritoneal macrophages firstly treated during 24 h
with TNF-a (10 ng/mL), PGN (1 mg/mL) or P. falciparum culture (P.f. c s) and then incubated during 20 h with sulforaphane (SFN) (10 mM) or
diethylmaleate (DEM) (100 mM) for protein quantification or 5 supplementary hours for mRNA detection. Data are represented as a mean 6 SD of
three independent experiments. **p,0.01 compared with the respective control (untreated);
##p,0.01 compared with the respective control (TNF-a
treated cells);
¤¤p,0.01 compared with the respective control (PGN treated cells);
11p,0.01 compared with the respective control (P.f. cs treated
cells);
dd p,0.01compared with control SFN-treated cells;
"" p,0.01compared to control DEM-treated cells. (C) Phagocytosis index of Pf PEs by Swiss
murine macrophages stimulated as described in (A). Data are represented as a mean 6 SD of three independent experiments. *p,0.05 and **p,0.01
compared with the respective control (untreated);
##p,0.01 compared with the respective control (TNF-a treated cells);
$$p,0.01 compared with
the respective control (SFN treated cells);
££p,0.01 compared with the respective control (TNF+SFN treated cells) (D) HO-1 mRNA level in Swiss
peritoneal macrophages determined by qRT-PCR after treatment of cells during 24 h with TNF-a (10 ng/mL) and then during 5 h with rosiglitazone
(R) (5 mM), IL13 (50 ng/mL) or SFN (10 mM). Data are represented as a mean 6 SD of three independent experiments. **p,0.01 compared with the
respective control (untreated);
##p,0.01 compared with the respective control (TNF-a treated cells).
doi:10.1371/journal.ppat.1002254.g002
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dently of PPARc. (A) PPARc protein level on Swiss murine peritoneal
macrophages and on RAW264.7 cells. The experiments were repeated three
times. (B) CD36 protein level on murine RAW264.7 cells after treatment of
cells with IL13 (50 ng/mL), rosiglitazone (R) (5 mM), sulforaphane (SFN)
(10 mM) or diethylmaleate (DEM) (100 mM). Data are represented as a mean
6 SD of three independent experiments. **p,0.01 compared with control
cells. (C) CD36 protein level detected by flow cytometry on Swiss murine
peritoneal macrophages firstly treated during 1 h with the PPARc
antagonists GW9662 (5 mM) and T007 (2 mM) and then incubated during
20 h with IL13, SFN or DEM. Data are represented as a mean 6 SD of three
independent experiments. **p,0.01 compared with the respective control
(untreated);
##p,0.01 compared with the respective control (GW9662
treated cells);
11p,0.01 compared with the respective control (T007 treated
cells). (D) CD36 mRNA level on PPARc
+/+ and PPARc
2/2 C57BL/6 murine
peritoneal macrophages after treatment of cells with rosiglitazone, IL13, SFN
or DEM. Data are from a representative experiment performed in triplicate 6
SD. The experiment was repeated three times. *p,0.05 and **p,0.01
compared with the respective control (PPARc
+/+);
##p,0.01 compared with
the respective control (PPARc
2/2). (E) Phagocytosis index of P. falciparum
unopsonized erythrocytes by murine PPARc
+/+ and PPARc
2/2 C57BL/6
macrophages stimulated as described in (E). Data are from a representative
experiment performed in triplicate 6 SD. The experiment was repeated
three times. *p,0.05 and **p,0.01 compared with the respective control
(PPARc
+/+);
#p,0.05 compared with the respective control (PPARc
2/2).
doi:10.1371/journal.ppat.1002254.g003
Figure 4. Nrf2 transcription factor is involved in CD36
overexpression during inflammatory processes. CD36 mRNA
level on Swiss peritoneal macrophages treated during 24 h with
TNF-a (10 ng/mL) (A) and on RAW264.7 cells (B) and transfected
with siRNA targeting Nrf2 (siRNA Nrf2) or control siRNA (siRNA
control) and stimulated with sulforaphane SFN (10 mM) or diethyl-
maleate (DEM) (100 mM). Data are represented as a mean 6 SD of
three independent experiments. *p,0.05 and **p,0.01 compared
with the respective control (cells transfected with siRNA control), (C)
CD36 mRNA level on Nrf2
+/+ and Nrf2
2/2 C57BL/6 murine peritoneal
macrophages after treatment during 24 h with TNF-a and then
incubated during 5 h with SFN or DEM. Data are from a
representative experiment performed in triplicate 6 SD. The
experiment was repeated three times **p,0.01 compared with
the respective control (Nrf2
+/+),
##p,0.01 compared with the
respective control (Nrf2
+/+ cells treated with TNF-a). (D) Phagocy-
tosis index of PfPEs by murine Nrf2
+/+ and Nrf2
2/2 C57BL/6
macrophages stimulated as described in (C). Data are from a
representative experiment performed in triplicate 6 SD. The
experiment was repeated three times. *p,0.05 and **p,0.01
compared with the respective control (Nrf2
+/+ control cells);
#p,0.05 compared with the respective control (Nrf2
+/+ cells treated
with TNF-a).
doi:10.1371/journal.ppat.1002254.g004
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the nucleus following SFN treatment both in noninflammatory
and in inflammatory (TNF-a) conditions. Altogether these results
confirm that after SFN treatment Nrf2 translocates to the nucleus
and exerts its transcriptional activity during inflammatory
conditions.
Nrf2 activators up-regulate CD36 and increase
phagocytosis of P. falciparum-PEs on human monocytes-
derived macrophages in inflammatory conditions
To extend our results to human monocytes-derived macrophages
(hMDMs), we evaluated the CD36 protein level on inflammatory
hMDMs following rosiglitazone, IL13, SFN or DEM treatments.
Cells were gated on the R1 region, corresponding to the hMDMs
population highly expressing CD36 (Fig. S4C). TNF-a, PGN and
P.f. cs downregulated CD36 protein and mRNA levels on hMDMs
(Fig. 6A, S4A, S4B). The increase of CD36 protein level in control
hMDMs following treatments by rosiglitazone, IL13, SFN and
DEM was only observed in TNF-a and PGN treated hMDMs after
SFN or DEM treatments. Indeed, rosiglitazone and IL13 did not
promote CD36 protein level inthese hMDMs (Fig. 6A, S4D). These
data confirm in humans that during inflammatory processes only
Nrf2 activators were able to promote CD36 expression. The failure
to promote CD36 expression on hMDMS via the PPARc signaling
pathway was associated with a marked reduction of PPARc mRNA
and protein levels (Fig. 6B) during acute inflammatory processes.
Finally, the ability of hMDMs to mediate the phagocytosis of
PfPEs under acute inflammatory processes was determined. Fig. 6C
reveals that SFN treatment promoted the phagocytosis of P.
falciparum both in noninflammatory (control) and inflammatory
(PGN) hMDMs. Phagocytosis both in normal and inflammatory
contexts was significantly inhibited by a CD36 specific antibody,
demonstrating that the induction of P. falciparum phagocytosis by
SFN treated hMDMs was dependent of CD36 receptor (Fig. 6C).
These data indicate that in humans during inflammatory
processes, only Nrf2 activators up-regulate CD36 expression on
hMDMs and P. falciparum phagocytosis-associated function.
Nrf2 but not PPARc activators improve in vivo severe
malaria outcome
Since we have demonstrated that Nrf2 regulates similarly CD36
receptor expression in inflammatory conditions both in human
Figure 5. Nrf2 activation by sulforaphane occurs even under inflammatory conditions. (A) Quantification of the ARE-nuclear binding of
Nrf2 by DNA-binding ELISA TransAM kit after treatment of Swiss peritoneal macrophages with TNF-a during 24 h and then during 1 h with SFN. The
data are expressed as relative arbitrary units. Data are from a representative experiment performed in triplicate 6 SD. The experiment was repeated
three times. *p,0.05 and **p,0.01 compared with control cells. (B) Nrf2 protein level in nuclei extracts of cells described in (A) (C) Confocal laser
microscopy on Swiss macrophages described in (A). The blue color represents the nucleus; the green color represents Nrf2. Merged images of the
blue and green colors are shown in the right-hand panels. The data are representative of three independent experiments.
doi:10.1371/journal.ppat.1002254.g005
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PLoS Pathogens | www.plospathogens.org 7 September 2011 | Volume 7 | Issue 9 | e1002254Figure 6. Nrf2 activators promote CD36 and increase P.falciparum clearance by human MDMs in inflammatory conditions. (A) CD36
protein level detected by flow cytometry on human-monocytes derived macrophages (hMDMs) firstly treated during 24 h with TNF-a (10 ng/mL) or
PGN (1 mg/mL) and then incubated during 20 h with rosiglitazone (R) (5 mM), IL13 (50 ng/mL), SFN (10 mM) or DEM (100 mM). Data are represented as
a mean 6 SD of three independent experiments. **p,0.01 compared with the respective control (untreated);
#p,0.05 compared with the respective
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macrophages, we developed an induced-inflammatory severe
malaria model in Swiss genetic background to validate that Nrf2
could be a therapeutic target in the prevention of severe malaria.
To establish this malaria model, Swiss mice were pre-treated
with peptidoglycan (PGN), a TLR2 activator, and then infected
with P. berghei. As expected, PGN-treated mice had a significantly
lower survival rate compared with control mice (p=0,043) which
did not succumb in the early phase of infection, demonstrating
that PGN-induced inflammatory processes strongly worsen the
outcome of infection in the Swiss mice model (Fig. 7A). In
addition, PGN treated mice presented significant higher parasit-
emia levels than control animals (Fig. 7B), but did not succumb
from anemia (data not shown). Altogether, these results indicate
that installed acute inflammatory processes before infection by
P. berghei in mice clearly worsen the severity of the infection.
To determine whether the PGN-induced increase in parasite
burden observed in our severe malaria model was associated with
macrophage CD36 downregulation, we evaluated the CD36
protein level on peritoneal macrophages. PGN treatment
significantly decreased CD36 protein level (Fig. 7E). Altogether
these data demonstrate that inflammatory processes induced by
PGN treatment in infected mice downregulate the macrophage
CD36 expression and contribute to worsen the severity of malaria
infection in mice.
To assess whether Nrf2 activators or PPARc ligands were able
to improve the outcome of severe malaria, PGN-induced severe
malaria mice were treated with SFN or rosiglitazone. The in vivo
oral treatment of mice with SFN initiated the day of infection and
followed 5 days post infection greatly increases the survival rates of
mice (p=0,0001) (Fig. 7C) and contributes to limit the parasite
burden in the first days of infection (Fig. 7D). The rosiglitazone
treatment increases the survival rates of PGN treated mice
(p=0,032) (Fig. 7C) and does not affect their blood parasitemia
level (Fig. 7D). Interestingly, the CD36 protein level on
macrophages only increased after in vivo SFN treatment (Fig. 7F),
demonstrating that in an in vivo acute inflammatory context only
Nrf2 activators and not PPARc ligands are able to up-regulate
CD36 expression. Finally, we demonstrate that macrophages from
infected SFN-treated mice enhance P. berghei clearance (Fig. 7H).
The use of anti-CD36 and anti-FcR antibodies demonstrates that
P. berghei-PEs were internalized in a CD36 dependent manner
(Fig. 7G). Altogether, these results strongly suggest that targeting
Nrf2 in vivo contributes to improve the outcome against in-
flammatory-induced severe malaria in mice.
Discussion
Mononuclear phagocytes play an important role in the
clearance of blood-stage malaria parasites resulting in an early
control of parasite proliferation during acute infection [5,20]. The
importance of CD36 receptor expression on macrophages in
malaria parasite clearance and in the regulation of parasite-
induced inflammatory processes has been demonstrated both in
vitro and in vivo on CD36
2/2 mice [5]. Recent data provide
evidence that rosiglitazone PPARc ligand can in vitro and in vivo
improves the outcome of experimental malaria in mice, enhancing
CD36-mediated PEs phagocytic processes and limiting parasite-
induced inflammatory processes [9]. Nevertheless, much of the
pathology associated with malaria infections is a result of excessive
and uncontrolled production of proinflammatory markers [11,21].
In this study, we demonstrated that inflammatory processes
induced by TNF-a or TLR2 ligands downregulate CD36
expression on Swiss murine and human macrophages. These data
are consistent with other studies, highlighting the deleterious effect
of LPS, IFNc or TNF-a treatment on CD36 expression
[13,14,22,23]. We also show that a similar CD36 downregulation
was observed on murine and human macrophages following Pfcs
treatment, which contains soluble factors released from infected
erythrocytes rupture such as PfGPI anchors (glycophosphatidyli-
nositol), described as TLR2 ligands [24]. In addition, we have
previously demonstrated that circulating human monocytes
presented a loss of CD36 expression during the acute phase of
plasmodial infection [12]. In parallel, we demonstrated that PGN
and P.f. cs treatments downregulate CD36 expression specifically
through TLR2. Surprisingly, the TLR2 activators-mediated CD36
dowregulation is independent of TNF-a release. In addition, we
demonstrate in this study that this decrease in CD36 expression on
macrophages impairs CD36-mediated PfPEs phagocytosis. Con-
sistent with these data, prostaglandin E2, a pro-inflammatory
eicosanoid, was shown to downregulate CD36 expression on
macrophage directly resulting in a reduced CD36-phagocytic
ability leading to the development of endometriosis [25].
PPARc ligands thiazolidinediones and IL4 or IL13, two Th2
cytokines known to activate PPARc, were previously shown in vitro
to promote CD36 expression and enhance CD36-mediated PEs
phagocytosis [4,6,8,9,26]. Surprisingly, our current results re-
vealed that PPARc ligands and IL13 have no effect on the
modulation of CD36 expression in inflammatory macrophages.
Consistent with this, TNF-a was previously shown to downreg-
ulate CD36 expression on human monocytes involving a direct
reduction in PPARc activation [13]. In line with these results, it
has been reported that inflammatory processes reduce PPARc
expression and activation, highlighting the deleterious effect of
inflammatory processes on PPARc [27–29]. Collectively, our data
provides compelling evidence that inflammatory processes nega-
tively regulate the expression of PPARc in swiss murine
macrophages and human monocyte-derived macrophages, result-
ing in a failure to trigger this pathway to promote CD36
expression and Plasmodium clearance. Interestingly, inflammatory
stimuli did not negatively regulate the expression of PPARc and
hence CD36 expression in C57BL/6 murine macrophages,
suggesting the importance of genetic background in their
regulation. Therefore, it seems that the Swiss mice model better
mimics the human model. Indeed, inflammatory processes inhibit
PPARc and CD36 in hMDMS, and monocytes from Plasmodium-
infected patients exhibit a CD36 dowregulation [12].
In our study, we demonstrated that PPARc
2/2 macrophages
did not present a totally abolished CD36 phenotype, suggesting
the existence of alternative pathways controlling CD36 expression
on macrophages. We also previously demonstrated that the
increase of the CD36 receptor following an anti-TNF-a antibody
treatment occurred independently of PPARc and involved radical
control (TNF-a treated cells);
¤¤p,0.01 compared with the respective control (PGN treated cells). (B) PPARc protein and mRNA levels on hMDMs
treated with TNF-a, LPS, P.f. cs and PGN. PPARc western blot is representative of three independent experiments and qPCR data are represented as a
mean 6 SD of three independent experiments. **p,0.01 compared with the respective control (untreated). (C) Phagocytosis index of P. falciparum
unopsonized erythrocytes by hMDMs stimulated as described in (A). Data are represented as a mean 6 SD of three independent experiments.
**p,0.01 compared with the respective control (untreated);
##p,0.01 compared with the respective control (PGN treated cells);
$$p,0.01 compared
with the respective control (SFN treated cells);
££p,0.01 compared with the respective control (TNF+SFN treated cells).
doi:10.1371/journal.ppat.1002254.g006
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PLoS Pathogens | www.plospathogens.org 9 September 2011 | Volume 7 | Issue 9 | e1002254Figure 7. Nrf2 activator sulforaphane improves the outcome of induced-severe malaria trough a reduction in parasite burden. Swiss
mice receiving PGN (200 mg/mouse) (subcutaneous route) two days before infection and d,L-sulforaphane (75 mg/kg) or rosiglitazone (3 mg/kg) (oral
route) during five days postinfection were infected with 1610
6 Plasmodium berghei parasites via intra-peritoneal injection. (A) and (C) Survival was
assessed twice daily. **p,0.01 compared with untreated mice (control),
¤¤p,0.01 compared with PGN-treated mice. (B) and (D) Parasitemia levels
were assessed daily. **p,0.01 compared with untreated macrophages (control);
¤p,0.05 and
¤¤p,0.01 compared with PGN-treated cells. (E) and (F)
CD36 expression on macrophages was measured the day of infection by flow cytometry on three independent mice. *p,0.05 compared with
untreated macrophages (control);
¤p,0.05 compared with PGN-treated cells. (G) Phagocytosis index of P. berghei unopsonized erythrocytes by Swiss
murine macrophages incubated with FcR blocking antibodies (20 mg/mL) and CD36 blocking antibodies (10 mg/mL). Data are presented as mean 6
SD of one experiment performed in triplicate. **p,0.01 compared to uRBC+a2FcR,
$p,0.05 compared with iRBC+a2CD36,
£p,0.05 compared with
iRBC+a2FcR. (H) Phagocytosis index of P. berghei unopsonized erythrocytes by 3 days-infected macrophages from Swiss mice treated with PGN and
SFN as described above.
¤p,0.05 compared with PGN-treated macrophages.
doi:10.1371/journal.ppat.1002254.g007
Nrf2 Promotes CD36 Antimalarial Activity
PLoS Pathogens | www.plospathogens.org 10 September 2011 | Volume 7 | Issue 9 | e1002254oxygen species production (ROS) via NADPH oxidase activation
[13]. The ROS are potent inducers of Nrf2 activation, a
transcription factor involved in the prevention of severe inflam-
matory diseases [16]. Interestingly, this transcription factor was
shown to play an important role in the regulation of CD36
expression on murine macrophages [18]. Thus, we postulated that
Nrf2 transcription factor might substitute PPARc to promote
CD36 expression during acute inflammatory processes. Consistent
with this hypothesis, we demonstrated that SFN or DEM, Nrf2
activators, upregulate CD36 expression both on murine and
hMDMs during inflammatory processes. This CD36 overexpres-
sion leads to a higher elimination rate of PfPEs by macrophages.
CD36 induction following SFN or DEM treatments was shown to
be PPARc independent and Nrf2 dependent. Altogether, these
data unequivocally demonstrate that the Nrf2 transcription factor
regulate CD36 expression in absence or in the presence of PPARc
nuclear receptor.
Serghides et al. have recently focused on the effects of PPARc
ligand treatment in an inflammatory cerebral malaria murine
model. The rosiglitazone treatment improves the survival rate of
mice with cerebral malaria. Nevertheless, time course adminis-
tration of rosiglitazone revealed that the rosiglitazone treatment
was a lot more efficient when administered one week before
infection than one day after the onset of the disease [9]. In our
induced-inflammatory severe malaria model, we demonstrated
that rosiglitazone administered after the onset of infection, when
the inflammatory processes are already triggered, has a very slight
effect compared with SFN effect on mice survival rate and no
effect on the modulation of parasitemia level. The positive in vivo
effect of rosiglitazone on Swiss mice survival may be associated to
a refractory population of macrophages to the inflammatory
mediated CD36 downregulation. The differences observed
between our study and the data published by the Kain’s group
are certainly related to the genetic background of the murine
models used. Indeed, we did not in fact observe in vitro the
downregulations of PPARc and CD36 on macrophages from
C57BL/6 mice in inflammatory conditions while PPARc and
CD36 were greatly impaired in swiss macrophages, as in
hMDMs. These data suggest that the benefit of using rosiglita-
zone depends on the modulation of PPARc expression which
seems to be dependent on individual genetic background. The
variability of rosiglitazone effectiveness in inflammatory processes
has already been observed in other studies. Preventive adminis-
tration of thiazolidinediones did in fact provide beneficial effects
in murine models of ulcerative colitis but was less efficient when
administered after the onset of the disease because PPARc was
shown to be downregulated by colitis-induced inflammatory
processes [30]. Similar results were observed in human patients
with colitis, which present a modest improvement in the outcome
of the disease after rosiglitazone treatment [31]. This rosiglita-
zone inefficiency could be directly related to an impairment of
PPARc expression observed in patients with inflammatory colitis
[32].
Interestingly, as opposed to the rosiglitazone treatment which
slightly decreases severe malaria infection, we demonstrated here
for the first time that the SFN, an Nrf2 activator, strongly
contributes to control the elevation of parasite burden and hence
consistently improves the outcome of severe inflammatory
induced-malaria. This was correlated to an induction of CD36
expression on macrophage following SFN treatment and with a
higher phagocytic capacity for PEs. In addition, SFN treatment
did not alter major pro- and anti-inflammatory cytokines involved
in malaria physiopathology (Fig. S5A, S5B), suggesting that SFN-
induced protection is essentially due to the uptake of parasites
through CD36 receptor. In addition, we showed that SFN
treatment also reduces parasitemia in Swiss infected mice without
prior PGN treatment (data not shown), indicating that the Nrf2
pathway is also important under more natural infection conditions.
Recently, a clinical study in humans described the effectiveness
of rosiglitazone as an adjunct treatment to standard therapy for
non severe malaria [33]. Nevertheless, although the effects of
rosiglitazone in combination with conventional antimalarial
treatments were effective in a non severe P. falciparum infection
associated with moderated and controlled inflammatory processes,
one question may subsist on the effectiveness of rosiglitazone when
administered during severe malaria when acute inflammatory
processes are engaged. We showed on human inflammatory
MDMs that the rosiglitazone treatment was ineffective on CD36-
mediated parasite clearance due to a downregulation of PPARc.
Interestingly, the Nrf2 activators treatments were able to promote
CD36 expression on human MDMs and hence participate actively
to the clearance of Plasmodium.
In conclusion, the present results provide direct evidence that
inflammatory processes and particularly malaria parasite-induced
inflammatory processes impair CD36 expression on Swiss murine
as on human MDMs and CD36-mediated phagocytosis, favoring
the worsening of malaria infection. This observation is correlated
to a failure in PPARc expression and activation. However, in
inflammatory conditions, we demonstrated that Nrf2 pathway
controls CD36 expression and improves the outcome of severe
malaria independently of PPARc. Thus, the results suggest the
possibility that Nrf2 may be a therapeutic target for the control of
severe malaria.
Materials and Methods
Ethics statement
This study was carried out in accordance with Approval No
B3155503 and all animal experiments followed the guiding
principles of animal care and use defined by the Conseil
Scientifique du Centre de Formation et de Recherche Experi-
mental Me ´dico Chirurgical (CFREMC) with the rules of Decree
87–848 dated 10/19/1987 (modified by Decree 2001-464 and
Decree 2001-131 relative to European Convention, EEC Directive
86/609 dated 24/11/1986). The experiments were approved by
the ethics board of the Midi-Pyre ´ne ´es ethic committee for animal
experimentation (Experimentation permit number 31-067).
Monocytes were obtained from healthy blood donors (Etablisse-
ment Franc ¸ais du Sang, Toulouse). Written informed consents
were obtained from the donors under EFS contract nu21/PVNT/
TOU/UPS04/2010–0025. Following articles L1243-4 and
R1243-61 of the French Public Health Code, the contract was
approved by the French Ministry of Science and Technology
(agreement nuAC 2009-921).
Animals
Female Swiss and C57BL/6 transgenic 6–12-week-old mice
were used both for in vitro and in vivo experiments. The generation
of the PPARc
2/2 [8] and Nrf2
2/2 [34] mouse lines were
previously described.
Mouse peritoneal macrophages isolation
Resident peritoneal cells were harvested by washing the
peritoneal cavity with sterile NaCl 0,9%. Collected cells were
centrifuged and the cell pellet was suspended in Macrophage-
Serum Free Medium (M-SFM) (Gibco Invitrogen). Cells were
allowed to adhere for 2 h at 37uC, 5% CO2. Non-adherent cells
were then removed by washing with PBS.
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macrophages
Human peripheral blood mononuclear cells were isolated from
the blood of healthy volunteers by a density gradient centrifuga-
tion method on Lymphoprep (Abcys). Monocytes were isolated by
adherence to plastic for 2 h in M-SFM at 37uC, 5% CO2.
Monocytes were cultured for 5–7 supplementary days in M-SFM
containing 50 ng/mL M-CSF (eBiosciences) to allow for differen-
tiation into human monocyte-derived macrophages.
P. falciparum culture and supernatant collection
The laboratory P. falciparum strain FcB1-Columbia presenting the
phenotype Knobs+ at the erythrocyte surface was continuously
cultured according to Trager and Jensen [35] with modifications
[36]. To obtain P. falciparum culture supernatant (P.f. cs) for in vitro
stimulations, parasites were highly synchronized by 5% D-Sorbitol
treatment (Sigma). After schizont stage-infected erythrocyte rupture
occurred, the culture medium was collected and centrifuged before
being used for in vitro experiments. For phagocytosis assays,
trophozoite-stage infected erythrocytes were washed and used at a
PEs macrophage ratio of 20:1. For P.berghei phagocytosis experi-
ments, we used a PEs macrophage ratio of 10:1.
Reagents
Murine peritoneal macrophagesand hMDMs werestimulated by
TNF-a (10 ng/mL) (eBiosciences), LPS (100 ng/mL) (Sigma
Aldrich), Peptidoglycan (PGN) (1 mg/mL) (Sigma Aldrich), rosi-
foglitazone (5 mM) (Cayman Chemical), IL-13 (50 ng/mL)
(eBiosciences), sulforaphane (SFN) (10 mM) (Sigma Aldrich),
diethylmaleate (DEM) (100 mM) (Sigma Aldrich), and by 500 mL
ofP.f. cs. Macrophageswere incubatedwiththe specificinhibitors of
PPARc, GW9662 (5 mM) and T0070907 (2 mM) (Cayman
Chemical),30 minbeforethe addition ofPPARc or Nrf2 activators.
Flow cytometry assay
Murine macrophage surface expression of CD36 was detected
as previously described [37]. Briefly, murine macrophage CD36
expression was detected using a PE-monoclonal CD36 antibody
(Santacruz, sc-13572) and compared with an irrelevant appropri-
ate isotype control (Santa Cruz, sc-3600). hMDMs macrophages
were stained with mouse IgM,k CD36-APC antibody (BD
Pharmingen). A mouse IgM,k isotype-matched antibody conju-
gated to APC (BD Pharmingen) was used as a control. A minimum
population of 3000 cells was analyzed for each data point. All
analyses were performed on a FACScan using CellQuestPro
software (Becton Dickinson).
Quantitative real-time PCR experiments
RNA and cDNA preparation were as described [38]. Quanti-
tative RT-PCR was performed on a LightCycler 480 system using
LightCycler 480 SYBR GREEN I MASTER (Roche Diagnostics).
b-actin was used as the invariant control. The sequences of
primers were listed in supplementary Table S1. The N-fold
differential expression of mRNA gene samples was expressed as
2
DDCt.
Fluorescence imaging confocal microscopy
Cells were fixed with PBS containing 4% paraformaldehyde
and were then incubated in a glycine solution (100 mM). After
permeabilization and blocking, cells were then incubated over-
night at 4uC with anti-Nrf2 antibody (Santacruz, sc-13032). Cells
were then incubated with Alexa 488-conjugated anti rabbit
antibody (Invitrogen) for 1 h at room temperature. Nuclei were
stained with DAPI. Treated cells were covered with glass slips
using Perma Fluor (Thermo Scientific). All microscopy imagery
was performed with a LEICA SP2 laser scanning confocal
microscope. For each condition, 40–50 cells were analyzed. The
staining is representative of three independent experiments.
Phagocytosis assays
Phagocytosis assays were performed as already described [8].
The phagocytic index was calculated as the percentage of
macrophages with PEs phagocytosed.
Transfection assays
Nrf2 siRNA (Santacruz sc-37049) and control siRNA (Santa-
cruz sc-37007) were transfected into RAW cells or Swiss murine
peritoneal macrophages using Lipofectamine 2000 reagent
(Invitrogen) as described in the manufacturer’s protocol.
Nuclear protein extraction and DNA-binding activity
Nuclear proteins were isolated with NE-PER kit (Thermo
Scientific). Nrf2 TransAM ELISA-kit (Active Motif) was used to
evaluate Nrf2 DNA-binding activity. The final A450 was read on a
microplate reader (Wallac 1420 Victor2).
Western blot and antibodies
Westen Blot experiments were performed as described [38].
Rabbit polyclonal IgG anti-PPARc (Santa Cruz Biotechnology, sc-
7196), rabbit polyclonal IgG anti-Nrf2 (Santacruz Biotechnology,
sc-13032) and goat polyclonal IgG anti-actin (Santacruz biotech-
nology, sc-1615) were used. Secondary polyclonal anti-goat or -
rabbit IgG HRP coupled Abs were used (Cell Signaling).
Murine malaria models
In vivo assays were performed with Plasmodium berghei. Parasites
were administered intraperitoneally (1.10
6 parasites/mouse) in
Swiss female 12 week-old mice. Studies were performed on
separate groups of 7 mice each infected and were repeated twice.
Two days before infection, mice were treated subcutaneously with
PGN (200 mg/mouse). Mice were then treated by oral route with
d,L-sulforaphane (Santacruz Bio) (75 mg/kg), rosiglitazone (3 mg/
kg) or with vehicule 5 days following the infection. The mice were
then monitored daily for parasitemia levels with thin blood smears
and survival was assessed twice daily.
Statistical analysis
For each in vitro experiments, the data were subjected to one-
way analysis of variance followed by the means multiple
comparison method of Bonferroni-Dunnet. p,0.05 was consid-
ered as the level of statistical significance. Survival studies were
done using 7 mice per group and were repeated twice. Statistical
significance was determined by a log-rank test.
Supporting Information
Figure S1 PPARc activators failed to increase CD36
expression in inflammatory conditions driven by TNF-a
or following TLR2 activation. (A) FACS data showing how
cells were gated in the R1 region, a macrophage population
double-labeled by the specific murine macrophage marker F4/80
and CD36. (B–C) Representative FACS profiles of CD36 in
control macrophages (light grey histogram) and TNF-a (10 ng/
mL) or P.f. cs-treated macrophages (dark grey histogram) after
rosiglitazone (5 mM) or IL-13 (50 ng/mL) stimulations.
(PDF)
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expression in inflammatory conditions. (A–B) Representa-
tive FACS profiles of CD36 in control macrophages (light grey
histogram) and TNF-a- (10 ng/mL) or P.f. cs-treated macrophag-
es (dark grey histogram) after DEM (100 mM) or SFN (10 mM)
stimulations. (C) CD36 protein level detected by flow cytometry on
Swiss murine peritoneal macrophages firstly incubated during
20 h with rosiglitazone (5 mM), IL13 (50 ng/mL), SFN (10 mM) or
DEM (100 mM) and treated during 24 supplementary hours with
TNF-a (10 ng/mL). Data are represented as a mean 6 SD of
three independent experiments. **p,0.01 compared with the
respective control (untreated).
##p,0.01 compared with the
respective control (TNF-a treated cells). (D) CD36 protein level
detected by flow cytometry on Swiss murine peritoneal macro-
phages firstly incubated during 20 h with TNF-a (10 ng/mL) and
treated during 24 supplementary hours with rosiglitazone (5 mM)
and SFN (100 mM). Data are represented as a mean 6 SD of three
independent experiments. **p,0.01 and *p,0.05 compared with
the respective control (untreated).
##p,0.01 compared with the
respective control (TNF-a treated cells). (E–F) PPARc mRNA
level on Swiss and C57BL/6 Nrf2
+/+ and Nrf2
2/2 murine
peritoneal macrophages after treatment with TNF-a (10 ng/mL)
during 24 h and then incubation during 5 supplementary hours
with SFN (10 mM) or DEM (100 mM). Data are from a
representative experiment performed in triplicate 6 SD. Exper-
iment has been repeated three times **p,0.01 and *p,0.05
compared with the respective control,
##p,0.01 and
#p,0.05
compared with the respective control.
(PDF)
Figure S3 Nrf2 dependent increase of HO-1 mRNA
expression on murine macrophages both in normal
and in inflammatory conditions. Nrf2 (A) and HO-1 (B)
mRNA expression on Swiss peritoneal macrophages after
treatment during 24 h with TNF-a (10 ng/mL) transfected with
siRNA targeting Nrf2 (siRNA Nrf2) or control siRNA (siRNA
control) and stimulated with sulforaphane (SFN) (10 mM) or
diethylmaleate (DEM) (100 mM). Data are represented as a mean
6 SD of three independent experiments. *p,0.05 compared with
control cells transfected with siRNA control,
¤p,0.05 compared
with cells transfected with siRNA control and stimulated by SFN.
1p,0.05 compared with cells transfected with siRNA control and
stimulated by DEM. (C) HO-1 mRNA level on Nrf2+/+ and
Nrf2-/- C57BL/6 murine peritoneal macrophages after treatment
during 24 h with TNF-a (10 ng/mL) and incubated during 5
supplementary hours with sulforaphane (SFN) (10 mM) or
dietylmaleate (DEM) (100 mM). Data are from a representative
experiment performed in triplicate 6 SD. Experiment has been
repeated three times. **p,0.01 compared with the respective
control (Nrf2
+/+),
##p,0.01 compared with the respective control
(Nrf2
+/+ cells treated with TNF-a).
(PDF)
Figure S4 Nrf2 but not PPARc activators promote CD36
expression on hMDMs inflammatory macrophages.
CD36 protein (A) and CD36 mRNA level (B) on human
monocyte-derived macrophages (hMDMs) was quantified by flow
cytometry or qRT-PCR experiments after treatment of cells with
TNF-a (10 ng/mL), PGN (1 mg/mL) or P.f. c s. Data are
represented as a mean 6 SD of three separate experiments.
*p,0.05 and **p,0.01 compared with control cells. (C) FACS
data showing how cells were gated in the R1 region, a human
macrophage population highly expressing CD36 (D) Representa-
tive FACS profiles of CD36 in control hMDMs (light grey
histogram) and PGN-treated hMDMs (dark grey histogram) after
rosiglitazone (5 mM), SFN (10 mM) or DEM (100 mM) stimula-
tions.
(PDF)
Figure S5 In vivo SFN treatment did not alter TNF-a,
IFN-c, IL-12, IL-10 cytokine mRNA levels in macrophag-
es. (A–B) mRNA levels of Nrf2 target genes and pro- or anti-
inflammatory markers on macrophages harvested from 3 days-
infected mice treated with PGN and SFN. Data are represented as
a mean 6 SD of 5 independent mice.
¤p,0.05 compared with
PGN treated cells.
(PDF)
Table S1 Murine and human primers sequences used
in quantitative PCR experiments.
(PDF)
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